Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,837.84 -39.21 (-0.50%) Bitcoin USD
65,077.56 +2,575.79 (+4.12%) CMC Crypto 200
1,336.58 +23.96 (+1.86%)
ABBV Jan 2025 135.000 put
| Previous close | 3.4700 |
| Open | 3.4700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 135.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.4700 - 3.4700 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.72k |
BenzingaSoon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults. The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total “on” time without tr
PR NewswirePhase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regime
ZacksAbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.
